A panelist discusses how polycythemia vera (PV) is a rare myeloproliferative neoplasm (MPN) characterized by excessive red blood cell production, primarily affecting older adults with JAK2 mutations, ...

MPNs involve overproduction of blood cells, while MDS results in poorly formed cells, affecting blood cell function and counts. Diagnosis requires blood tests, bone marrow biopsy, and genetic testing ...

The blood you don’t need could be exactly what someone else is praying for. It sounds inconceivable, yet for patients requiring frequent therapeutic phlebotomy—blood removal as treatment—this blood is ...

Expression of CD47 and CALR in myeloproliferative neoplasms: Potential new therapeutical targets. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a ...

Polycythemia vera (PV) therapy should aim to identify cardiovascular risk factors, according to one review. Diagnosis and management of cardiovascular (CV) events including stroke, heart attacks, and ...

Data suggest a substantial reliance on established therapies for polycythemia vera, despite access to all available treatment options. Currently available treatments for polycythemia vera (PV) may not ...

Rusfertide, an investigational, first-in-class, self-injected peptide targeting the hepcidin pathway, shows efficacy in significantly reducing the need for phlebotomy in patients with polycythemia ...

Impact of rurality on patients with synchronous colorectal cancers. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.